All Outputs (7)

Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial (2019)
Journal Article
Schmid, P., Abraham, J., Chan, S., Wheatley, D., Murray Brunt, A., Nemsadze, G., …C. Turner, N. (2020). Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial. Journal of Clinical Oncology, 38(5), 423 - 433. https://doi.org/10.1200/JCO.19.00368

PURPOSE: The phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway is frequently activated in triple-negative breast cancer (TNBC). The AKT inhibitor capivasertib has shown preclinical activity in TNBC models, and drug sensitivity has been assoc... Read More about Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial.

Synchronous versus sequential chemo-radiotherapy in patients with early stage breast cancer (SECRAB): A randomised, phase III, trial (2019)
Journal Article
Fernando, I. N., Bowden, S. J., Herring, K., Brookes, C. L., Ahmed, I., Marshall, A., …Rea, D. W. (2020). Synchronous versus sequential chemo-radiotherapy in patients with early stage breast cancer (SECRAB): A randomised, phase III, trial. Radiotherapy and Oncology, 142, 52-61. https://doi.org/10.1016/j.radonc.2019.10.014

BACKGROUND: The optimal sequence of adjuvant chemotherapy and radiotherapy for breast cancer is unknown. SECRAB assesses whether local control can be improved without increased toxicity. METHODS: SECRAB was a prospective, open-label, multi-centre, ph... Read More about Synchronous versus sequential chemo-radiotherapy in patients with early stage breast cancer (SECRAB): A randomised, phase III, trial.

Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor–Positive Metastatic Breast Cancer (2019)
Journal Article
Schmid, P., Zaiss, M., Harper-Wynne, C., Ferreira, M., Dubey, S., Chan, S., …Cortés, J. (2019). Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor–Positive Metastatic Breast Cancer. JAMA Oncology, 5(11), 1556 - 1556. https://doi.org/10.1001/jamaoncol.2019.2526

IMPORTANCE: Randomized clinical trials have demonstrated a substantial benefit of adding everolimus to endocrine therapy. Everolimus inhibits the mammalian target of rapamycin complex 1 (mTORC1) complex but not mTORC2, which can set off an activating... Read More about Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor–Positive Metastatic Breast Cancer.

Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial (2019)
Journal Article
Mittendorf, E. A., Lu, B., Melisko, M., Price Hiller, J., Bondarenko, I., Brunt, A. M., …Peoples, G. E. (2019). Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial. Clinical Cancer Research, 25(14), 4248-4254. https://doi.org/10.1158/1078-0432.ccr-18-2867

long term follow-up of FoRT: a phase 3 multi-center prospective randomized trial of radiation therapy for follicular and marginal zone lymphoma (2019)
Journal Article
Hoskin, P., Kirkwood, A., Popova, B., Schofield, O., Brammer, C., Robinson, M., …Clifton-Hadley, L. (2019). long term follow-up of FoRT: a phase 3 multi-center prospective randomized trial of radiation therapy for follicular and marginal zone lymphoma. Hematological Oncology, 37(S2), 219 - 220. https://doi.org/10.1002/hon.34_2630

Supplement article.

16. Can patients with multiple breast cancers in the same breast avoid mastectomy by having multiple lumpectomies to achieve equivalent rates of local breast cancer recurrence? A randomized controlled feasibility trial called MIAMI UK (NCT03514654) (2019)
Journal Article
Winters, Z., Roberts, N., McCartan, N., Potyka, I., Brunt, M., Maxwell, A., …Williams, N. (2019). 16. Can patients with multiple breast cancers in the same breast avoid mastectomy by having multiple lumpectomies to achieve equivalent rates of local breast cancer recurrence? A randomized controlled feasibility trial called MIAMI UK (NCT03514654). EJSO - European Journal of Surgical Oncology, 45(5), 881. https://doi.org/10.1016/j.ejso.2019.01.202

Background: Oncological safety of treating multiple ipsilateral breast cancers (MIBC) using therapeutic mammoplasty (TM) compared to mastectomy remains uncertain. A National Institute for Health Research (NIHR) - funded MIAMI feasibility phase random... Read More about 16. Can patients with multiple breast cancers in the same breast avoid mastectomy by having multiple lumpectomies to achieve equivalent rates of local breast cancer recurrence? A randomized controlled feasibility trial called MIAMI UK (NCT03514654).

Can patients with multiple breast cancers in the same breast avoid mastectomy by having multiple lumpectomies to achieve equivalent rates of local breast cancer recurrence? A randomised controlled feasibility trial called MIAMI UK (2019)
Journal Article
Brunt. (2019). Can patients with multiple breast cancers in the same breast avoid mastectomy by having multiple lumpectomies to achieve equivalent rates of local breast cancer recurrence? A randomised controlled feasibility trial called MIAMI UK. Annals of Surgical Oncology, 58 - 60

Meeting abstract, from the 20th Annual Meeting of the American-Society-of-Breast-Surgeons Conference, Dallas, Texas, 30 Apr - 5 May, 2019.